NTB-A Antibodies Targeting Hematologic Malignancies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody therapies for cancer often face challenges due to cross-reactivity with normal cells expressing similar antigens, limiting their effectiveness in targeting tumor-specific antigens and necessitating the development of agents that specifically recognize and bind to NTB-A, a molecule implicated in hematologic malignancies and hyperproliferative disorders.
Innovation Solution
Development of isolated antibodies and antigen-binding fragments with high affinity for NTB-A epitopes, including chimeric, humanized, or human antibodies, such as those with specific heavy and light chain variable regions, to target NTB-A expressed on hematopoietic cells, enabling precise diagnosis and treatment of NTB-A associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibody therapies are used to target tumor antigens, then cancer treatment is achieved, but cross-reactivity with normal cells occurs leading to detrimental effects
Solution Approach 1:
The patent applies local quality by creating antibodies with highly specific binding characteristics tailored to recognize unique structural features of NTB-A on tumor cells. The antibodies are engineered to bind specifically to epitopes present on NTB-A expressed by hematologic malignancy cells while avoiding binding to normal cells, thereby achieving localized specificity at the molecular recognition level.
Solution Approach 2:
The patent employs parameter changes by modifying antibody properties such as affinity, specificity, and binding characteristics to optimize their interaction with NTB-A. Through systematic variation of antibody parameters including binding constant, epitope recognition patterns, and structural configuration, the invention achieves enhanced differentiation between tumor cells and normal cells, reducing cross-reactivity while maintaining treatment effectiveness.
2Reliability
If antibodies with high affinity for tumor antigens are developed, then treatment efficacy is enhanced, but specificity becomes more difficult to maintain
Solution Approach 1:
The patent applies segmentation by dividing the antibody structure into distinct functional regions including variable domains for antigen recognition and constant domains for effector functions. By separately optimizing each segment, particularly the complementarity-determining regions (CDRs) that bind to NTB-A epitopes, the invention achieves high affinity while maintaining specificity through precise control of individual binding domain characteristics.
Solution Approach 2:
The patent uses intermediary structures such as framework regions and hinge domains that mediate between the variable binding regions and the constant effector regions. These intermediary elements provide structural stability and proper orientation, allowing the antibody to achieve high affinity binding to NTB-A while maintaining correct spatial configuration for specific recognition, thus balancing efficacy and specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These antibodies effectively bind to NTB-A with high specificity, facilitating therapeutic interventions and diagnostic methods for hematologic malignancies, reducing the risk of cross-reactivity with normal cells and enhancing treatment efficacy.
Implementation Method 1
isolated antibodies or immunologically functional antibody fragments (i.e. antigen-binding fragments) thereof that bind NTB-A epitopes with high affinity
Data Source
AI summary
Anti-NTB-A antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind NTB-A and treat diseases, such as hematologic malignancies, which are characterized by expression of NTB-A.